Further to the announcement by Advanced Tissue Sciences, Inc. (ATIS) that it is filing a voluntary petition for reorganisation under Chapter 11 of the US Bankruptcy Code, Smith & Nephew plc, the global advanced medical devices company, announces that ATIS is petitioning the court concerned to allow Smith & Nephew to acquire ATIS' 50% share of the DERMAGRAFT◊ joint venture for $12m.
ATIS is a US-based tissue engineering company and Smith & Nephew's partner in a joint venture for the marketing and manufacture of DERMAGRAFT®, a tissue-engineered dermal replacement for use in treating hard-to-heal diabetic foot ulcers, and TRANSCYTE®, a temporary skin cover for treating serious burns.
Subject to certain conditions and the approval of the bankruptcy court, the acquisition should be completed by the end of the year. In the meantime Smith & Nephew will work with the management of ATIS and advance up to $5m of the acquisition consideration, so as to maintain continuity of supply of DERMAGRAFT® and TRANSCYTE® and achieve an orderly transition of skills and resources from ATIS.
The acquisition of ATIS' share of the joint venture will require Smith & Nephew to bear an increased share of the start-up costs of the venture of some $18m over 2003 and 2004. This is more than counterbalanced by the benefit of attaining full control and with breakeven targeted in 2005 and 100% of profits thereafter. Smith & Nephew's underlying mid-teens EPS growth target remains unchanged.
Since the US launch of DERMAGRAFT® last year, clinicians have received the product favourably and reimbursement for DERMAGRAFT® is progressing to plan. Coverage policies for the use of DERMAGRAFT® in treating diabetic foot ulcers have now been established to cover about half of the potential Medicare beneficiaries. Combined sales of DERMAGRAFT® and TRANSCYTE® are expected to reach $8 million during 2002.
Chris O'Donnell, Chief Executive of Smith & Nephew, said: "DERMAGRAFT® and TRANSCYTE® are offering excellent therapeutic benefits to patients. Whilst it is disappointing that Advanced Tissue Sciences cannot continue to fund the DERMAGRAFT® joint venture, we believe it will benefit both Smith & Nephew and wound care patients to acquire control and realise the full potential of these products."